We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead PR Newswire LONDON, January 21, 2019 LONDON, January 21, 2019 /PRNewswire/ -- BTG plc...
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims PR Newswire PHILADELPHIA, January 8, 2019 PHILADELPHIA, January 8, 2019 /PRNewswire/ -- Distributed ledger technology is a game...
BTG Announces National Reimbursement for TheraSphere® in France PR Newswire LONDON, December 21, 2018 LONDON, December 21, 2018 /PRNewswire/ -- An estimated 500 patients per year in France could...
BTG Announces Global Launch of the ICEfx™ Cryoablation System PR Newswire LONDON, September 20, 2018 LONDON, September 20, 2018 /PRNewswire/ -- The ICEfx™ Cryoablation system is a compact and...
BTG PLC 15 June 2018 Result of FDA Advisory Committee vote on Elevair(TM) for the treatment of severe emphysema London, UK, 15 June 2018: BTG plc (LSE: BTG), the global specialist healthcare...
ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx™ Endobronchial Coil System PR Newswire LONDON, June 11, 2018 LONDON, June...
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC Based on experience with 1000 patients over 15 years, the largest single-centre prospective...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions